EHA Library - The official digital education library of European Hematology Association (EHA)
Magrolimab combination with azacitidine enhances therapeutic... | Download Scientific Diagram
Brian Skorney on Twitter: "Magrolimab + aza data out. CR rate in 2019 was 50% in high risk MDS. Down to 42% in 2020. Now 33% today. Contrast with 32% CR with
Magrolimab - Multiple Myeloma Clinical Trials
FORTY SEVEN, INC.
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma | Future Oncology
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma - ScienceDirect
Visual abstract | Azacitidine with venetoclax and magrolimab in patients with ND or R/R AML
Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy | Signal Transduction and Targeted Therapy
ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML
Magrolimab Achieving Positive Results in Phase 1b Trial of Untreated AML
PhI/II AZA/VEN/MAG - Slideset Download - | CCO
Magrolimab + Azacitidine vs Venetoclax Acute Myeloid Leukemia
Frontiers | Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Corporate Overview
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram
Forty Seven: Early Indications Suggest Magrolimab Could Be A Winner (NASDAQ:FTSV) | Seeking Alpha
ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML
Forty Seven: Buy The Dip In This CD47 Pioneer Ahead Of ASCO GI (NASDAQ:FTSV) | Seeking Alpha
New directions for emerging therapies in acute myeloid leukemia: the next chapter | Blood Cancer Journal
ASCO News - Magrolimab in Combination with Azacitidine Demonstrates Durable Activity in Untreated MDS & AML | Leukemia and Lymphoma Society
EHA Library - The official digital education library of European Hematology Association (EHA)
Forty Seven: Early Indications Suggest Magrolimab Could Be A Winner (NASDAQ:FTSV) | Seeking Alpha
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram
Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia-CliniExpert
Forty Seven: Buy The Dip In This CD47 Pioneer Ahead Of ASCO GI (NASDAQ:FTSV) | Seeking Alpha
JCM | Free Full-Text | Current Therapy of the Patients with MDS: Walking towards Personalized Therapy
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients | Leukemia and Lymphoma Society
